Advanced search

Find pages with...
Then narrow your results by...

About 77 search results

Pulmicort Turbuhaler (budesonide) powder for oral inhalation - Potential device failure - For the Public

... Program toll-free at 1-866-234-2345, or visit the MedEffect™ Canada Web site for information on how to report. The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. For other health product inquiries related to this communication, please contact Health Canada at: Health

Heath Canada warns consumers about unauthorized drugs sold online

... products from, such as clomid (clomiphene), salbutamol, tadalafil, tamoxifen, clenbuterol, andarine, ostarine, trestolone, and cardarine. What you should do Stop using these products. Consult with your health care professional if you have used any of these products and have concerns or require treatment for your medical condition. Read product labels

Search results

Mar 30, 2012 ...Search interface for Health Canada website

Duchesnay Inc. recalls certain lots of PregVit and PregVit folic 5 prenatal and postpartum vitamin-mineral supplements because of a packaging error

Nov 15, 2019 ...Duchesnay Inc. recalls certain lots of PregVit and PregVit folic 5 prenatal and postpartum vitamin-mineral supplements because of a packaging error Report a Concern Starting date: November 15, 2019 Type of communication: Advisory Subcategory: Drugs Source of recall: Health Canada Issue: Labelling and Packaging Audience: General Public, Healthcare

Labelling error may lead to patients receiving Linessa 28 birth control pills instead of Linessa 21

Jun 12, 2019 ... is incorrectly labelled with the eight-digit Drug Identification Number (DIN) for Linessa 21 (02272903) instead of the correct Linessa 28 DIN (02257238). The labelling error could result in a Linessa 21 patient inadvertently receiving Linessa 28 instead of Linessa 21 if the product is dispensed at the pharmacy only using the incorrect DIN as a reference. There is a small

Important Information About the Risk of Dosing Error for Tamiflu (oseltamivir phosphate) Powder for Oral Suspension (12 mg/mL) - For Health Professionals

... and the pharmacy prescription label should provide dosing instructions in milligrams (mg). If prescription instructions specify administration using milliliters (mL) or teaspoons (tsp), then the oral dosing dispenser included in the TAMIFLU product package should be removed and replaced with an appropriate measuring device, such as an oral syringe. Currently, the supply

Archived – A Small Number of Bottles of the Antibiotic Rofact® (Rifampin) May Contain a Different Drug

Apr 24, 2013 ... to a consumer, therefore at most three bottles may be on the Canadian market. Prescriptions of Rofact® may be dispensed from a pharmacy in smaller amounts and not in the original bottle. The incorrectly labelled bottles of Rofact® may have been on the Canadian market since December 2008. You can report any adverse reactions associated with the use of health products

Archived – Serious Risk of Infection From Ultrasound and Medical Gels – Revision

Jun 5, 2013 ... deficiencies: for example, gel containers are placed in a warming device, without a cap and for extended periods of time, refillable squeeze bottles are not cleaned between refills, non-sterile gels labelled for external use only are used on mucous membranes or during invasive procedures like biopsies. In order to minimize the health risks associated with the use

Archived – Obligations of Pharmacists under the Food and Drugs Act and Food and Drug Regulations

Jun 5, 2013 ..." is defined in C.01A.001 of the Food and Drug Regulations as to sell any drug listed in Schedule C or D to the Act or in Schedule F to the Regulations, a controlled drug as defined in G.01.001(1), or a narcotic as defined in the Narcotic Control Regulations, other than at retail sale, where the seller's name does not appear on the label of the drug. C.01A.004. (1

Archived – Important Safety Information Regarding Medication Errors Resulting from Confusion Between Seroquel® and Serzone-5HT2® – AstraZeneca and Bristol-Myers Squibb

Jun 4, 2013 ... relationship has not been established. According to the medication error reports, verbal and written prescriptions were incorrectly interpreted, labelled, and/or filled due to the similarity in names between Seroquel® and Serzone®. Furthermore, the overlapping strengths (100 mg and 200 mg), the dosage forms (tablets), the dosing interval (BID), and the fact

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: